Eisai sunsets development, access program for withdrawn obesity med in Dravet syndrome

In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor agonist lorcaserin.

Eisai has formally terminated a phase 3 study of lorcaserin as a potential adjunct treatment for patients with Dravet syndrome, a rare form of epilepsy that starts in infancy, according to the federal study repository clinicaltrials.gov.